Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
Language English Country Switzerland Media print-electronic
Document type Journal Article, Practice Guideline
PubMed
30177291
DOI
10.1016/j.eururo.2018.08.008
PII: S0302-2838(18)30593-1
Knihovny.cz E-resources
- Keywords
- Cytoreductive nephrectomy, EAU guidelines, Metastatic, Renal cell cancer, Sunitinib,
- MeSH
- Chemotherapy, Adjuvant MeSH
- Cytoreduction Surgical Procedures * methods standards MeSH
- Delphi Technique MeSH
- Adult MeSH
- Equivalence Trials as Topic MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Carcinoma, Renal Cell * secondary surgery MeSH
- Clinical Decision-Making MeSH
- Clinical Trials, Phase III as Topic standards MeSH
- Middle Aged MeSH
- Humans MeSH
- Evidence-Based Medicine standards MeSH
- Neoplasms, Multiple Primary * pathology surgery MeSH
- Kidney Neoplasms * pathology surgery MeSH
- Nephrectomy * methods standards MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Urology * standards MeSH
- Patient Selection MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Geographicals
- Europe MeSH
- Names of Substances
- Protein Kinase Inhibitors MeSH
Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear-cell renal cancer who present with the tumour in place. The CARMENA trial compared systemic therapy alone with CN followed by systemic therapy. This article outlines the new guidelines based on these data. PATIENT SUMMARY: The CARMENA trial demonstrates that immediate cytoreductive nephrectomy should no longer be considered the standard of care in patients diagnosed with intermediate and poor risk metastatic renal cell carcinoma when medical treatment is required. However, the psychological burden poor risk patients experience hearing that removal of their primary tumour will not be beneficial, should be carefully considered.
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Clinical Sciences Lund Lund University Skåne University Hospital Malmö Sweden
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Urology and Urologic Oncology Hannover Medical School Hannover Germany
Department of Urology Cabueñes Hospital Gijón Spain
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Elbe Kliniken Stade Stade Germany
Department of Urology Ludwig Maximilians University Munich Germany
Department of Urology Sunderby Hospital Sunderby Sweden
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University of Rennes Rennes France
Division of Urology Maggiore della Carità Hospital University of Eastern Piedmont Novara Italy
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
References provided by Crossref.org
